Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy
    Meeting Abstract

    Cercek, A.; Dos Santos Fernandes, G.; Roxburgh, C.; Ng, S.; Yaeger, R.; Segal, N.; Ganesh, K.; Reidy, D.; Smith, J. J.; Nash, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
    Meeting Abstract

    Choueiri, T. K.; Flaifel, A.; Xie, W.; Braun, D.; Ficial, M.; Jennings, R.; Nassar, A.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies
    Meeting Abstract

    Galon, J.; Mlecnik, B.; Hermitte, F.; Marliot, F.; Bifulco, C.; Lugli, A.; Nagtegaal, I. D.; Hartmann, A.; van den Eynde, M.; Roehrl, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer
    Meeting Abstract

    Arkenau, H. T.; Tabernero, J.; Shitara, K.; Dvorkin, M.; Mansoor, W.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
    Meeting Abstract

    Autio, K. A.; Naing, A.; Hung, A.; Oft, M.; Leveque, J.; Falchook, G. S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA)
    Meeting Abstract

    Agarwal, N.; Sokol, E. S.; Lara, P. Jr; Ross, J. S.; Miller, V. A.; Welsh, A. W.; Gregg, J. P.; Frampton, G. M.; Ali, S. M.; Chung, J.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Yau, T.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Banu, E.; Sarker, D.; Tan, B.; van Vlierberghe, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
    Meeting Abstract

    Shitara, K.; Tabernero, J.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
    Meeting Abstract

    Sakai, H.; Felip, E.; Cortot, A. B.; Veillon, R.; Griesinger, F.; Patel, J.; Horn, L.; Mazieres, J.; De Castro Carpeno, J.; Morise, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Friedlander, M.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save